Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Phase 2a study of nilotinib in patients with advanced and early Parkinson's disease. Study design
Movement Disorders
P5 - (-)
068
Authors/Disclosures
Tanya Simuni, MD, FAAN (Northwestern University Feinberg School of Medicien)
PRESENTER
Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for cadia, AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, Michael J Fox Foundation, Neuroderm, Sanofi, Sinopia, Roche, Takeda and Vanqua Bio. Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for of Koneksa, Neuroderm, Sanofi, UCB, AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche. Dr. Simuni has received research support from Amneal, Biogen, Neuroderm, Prevail, Roche, and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation.
No disclosure on file
Kalpana Merchant No disclosure on file
Christopher Coffey, PhD, FAAN (University of Iowa) Dr. Coffey has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Coffey has received research support from NIH. The institution of Dr. Coffey has received research support from Michael J Fox Foundation.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David K. Simon, MD, PhD (Beth Israel Deaconess Medical Center) Dr. Simon has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Bial Biotech. An immediate family member of Dr. Simon has stock in Biogen. The institution of Dr. Simon has received research support from Weston Brain Institute. The institution of Dr. Simon has received research support from NIH. The institution of Dr. Simon has received research support from Neuraly. Dr. Simon has received personal compensation in the range of $5,000-$9,999 for serving as a Steering Committee Member: SPARK clinical study with Biogen. Dr. Simon has received personal compensation in the range of $500-$4,999 for serving as a Steering Committee Member: NILO-PD clinical study with Michael J Fox Foundation.
Michael Schwarzschild, MD, PhD (Massachusetts General Hospital) The institution of Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial Biotech (indirectly, as a service of the Parkinson Study Group service). The institution of Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen (indirectly, as a service of the Parkinson Study Group service). The institution of Dr. Schwarzschild has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB (indirectly, as a service of the Parkinson Study Group service). Dr. Schwarzschild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Dr. Schwarzschild has received research support from NIH. The institution of Dr. Schwarzschild has received research support from Parkinson's Foundation. The institution of Dr. Schwarzschild has received research support from Michael J Fox Foundation. The institution of Dr. Schwarzschild has received research support from Farmer Family Foundation. Dr. Schwarzschild has a non-compensated relationship as a Chair, Executive Committee with the Parkinson Study Group that is relevant to AAN interests or activities.
David Weiner, MD No disclosure on file
Charles S. Venuto, MD No disclosure on file
No disclosure on file